Hisamitsu Pharmaceutical Co (FSE:4530) Cyclically Adjusted Revenue per Share: 円1,921.68 (As of Nov. 2025)


FSE:4530 Hisamitsu Pharmaceutical Co Inc FSE:4530
89 GF Score
Price 円3,975.00
GF Value 円3,237.07
View Full Analysis

What is Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Hisamitsu Pharmaceutical Co FSE:4530 89 Cyclically Adjusted Revenue per Share is 円1,921.68 as of Nov. 2025. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hisamitsu Pharmaceutical Co's adjusted revenue per share for the three months ended in Nov. 2025 was 円551.028. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,921.68 for the trailing ten years ended in Nov. 2025.

During the past 12 months, Hisamitsu Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hisamitsu Pharmaceutical Co was 2.70% per year. The lowest was -0.30% per year. And the median was -0.10% per year.

As of today (2026-07-09), Hisamitsu Pharmaceutical Co's current stock price is 円3975.00. Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Nov. 2025 was 円1,921.68. Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.07.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hisamitsu Pharmaceutical Co was 4.97. The lowest was 2.06. And the median was 2.88.


Hisamitsu Pharmaceutical Co  (FSE:4530) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3975.00/1921.68
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hisamitsu Pharmaceutical Co was 4.97. The lowest was 2.06. And the median was 2.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,740.21 1,776.49 1,813.84 1,886.38 0.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,886.38 1,898.39 1,902.21 1,921.68 0.00

FSE:4530 vs ESPR, AMPH, ETON: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


FSE:4530
89GF Score
Hisamitsu Pharmaceutical Co Inc FSE:4530
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hisamitsu Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Nov. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Nov. 2025 (Change)*Current CPI (Nov. 2025)
=551.028/113.2000*113.2000
=551.028

Current CPI (Nov. 2025) = 113.2000.

Hisamitsu Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201602 467.001 97.800 540.537
201605 450.523 98.200 519.340
201608 426.762 97.900 493.457
201611 415.821 98.600 477.393
201702 432.372 98.100 498.925
201705 431.029 98.600 494.853
201708 446.523 98.500 513.161
201711 430.936 99.100 492.250
201802 464.738 99.500 528.727
201805 400.203 99.300 456.223
201808 428.532 99.800 486.070
201811 396.542 100.000 448.886
201902 491.754 99.700 558.341
201905 353.457 100.000 400.113
201908 413.191 100.000 467.732
201911 436.176 100.500 491.295
202002 512.521 100.300 578.438
202005 304.680 100.100 344.553
202008 342.476 100.100 387.296
202011 341.102 99.500 388.068
202102 411.929 99.800 467.238
202105 339.551 99.400 386.692
202108 376.346 99.700 427.306
202111 344.569 100.100 389.662
202202 419.550 100.700 471.629
202205 330.922 101.800 367.980
202208 416.199 102.700 458.751
202211 404.595 103.900 440.810
202302 465.612 104.000 506.801
202305 412.593 105.100 444.391
202308 448.636 105.900 479.562
202311 467.826 106.900 495.397
202402 512.767 106.900 542.986
202405 477.314 108.100 499.833
202408 539.732 109.100 560.015
202411 484.175 110.000 498.260
202502 607.941 110.800 621.109
202505 474.551 111.800 480.493
202508 555.704 112.100 561.157
202511 551.028 113.200 551.028

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,921.68 mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a Cyclically Adjusted Revenue per Share of 円1,921.68 as of Nov. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Hisamitsu Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,921.68. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円1,921.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,921.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Cyclically Adjusted Revenue per Share of 円1,921.68. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,921.68. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Cyclically Adjusted Revenue per Share is 円1,921.68 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

  • Cyclically Adjusted Revenue per Share: 円1,921.68
  • GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score

Get the complete analysis for FSE:4530

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00
Price
円3,237.07
GF Value